Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 2/20 | 0.37 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | MMP12 | P39900 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | MMP14 | P50281 | 2/20 | 0.36 |
| ▸ | MMP16 | P51512 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8078709 | 0.83 | MYC (0.41) | MYCTSHRSMN1; SMN2TTRPGAM1 | |
| SCHEMBL11725194 | 0.79 | MYC (0.36) | MYCTSHRSMN1; SMN2TTRPGAM1 | |
| SCHEMBL11715136 | 0.79 | SRC (0.40) | MYCTSHRSMN1; SMN2TTRPGAM1 | |
| SCHEMBL29353004 | 0.77 | HSD11B1 (0.47) | MYCTSHRSMN1; SMN2TTRMMP1 | |
| SCHEMBL29617 | 0.77 | HSD11B1 (0.47) | MYCTSHRSMN1; SMN2TTRMMP1 | |
| SCHEMBL9098597 | 0.77 | MYC (0.44) | MYCTSHRSMN1; SMN2TTRPGAM1 | |
| SCHEMBL27273870 | 0.77 | TTR (0.42) | MYCTSHRSMN1; SMN2TTRPGAM1 | |
| SCHEMBL779332 | 0.77 | MYC (0.40) | MYCTSHRSMN1; SMN2TTRPGAM1 | |
| SCHEMBL9617134 | 0.77 | TTR (0.42) | MYCTSHRSMN1; SMN2TTRPGAM1 | |
| SCHEMBL10569917 | 0.77 | MYC (0.40) | MYCTSHRSMN1; SMN2TTRPGAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20080249184-A1 | Methods for modulating neuronal cell death | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2008-10-09 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | KIACTA SARL (CH) | 2006-06-01 | — | — | US | disclosed |
| EP-1614432-A2 | Method for treating amyloidosis | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-01-11 | — | — | EP | disclosed |
| EP-1609467-A1 | Compositions for treating diseases associated with glycosaminoglycan-associated molecular interactions | Neurochem (International) Limited (CH) | 2005-12-28 | — | — | EP | disclosed |
| US-20040220138-A1 | Methods for modulating neuronal cell death | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-11-04 | — | — | US | disclosed |
| US-6670399-B2 | Contacting a blood vessel wall cell with an A beta 40 inhibitor, such that cerebral amyloid angiopathy is inhibited | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2003-12-30 | — | — | US | disclosed |
| CN-1434706-A | Compounds and methods for modulating cerebral anyloid angiopathy | NEWROCHEM INC (CA) | 2003-08-06 | — | — | CN | disclosed |
| US-20030003141-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2003-01-02 | — | — | US | disclosed |
| US-6310073-B1 | ADMINISTERING TO SUBJECT THERAPEUTICALLY EFFECTIVE AMOUNT OF 3-AMINO-1-PROPANESULFONIC ACID, OR PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF, SUCH THAT GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTION IS MODULATED AND CONDITION IS TREATED | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2001-10-30 | — | — | US | disclosed |
| EP-1100487-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | Neurochem, Inc. (CA) | 2001-05-23 | — | — | EP | disclosed |
| EP-1077690-A1 | USE OF AMYLOID INHIBITORS FOR MODULATING NEURONAL CELL DEATH | Neurochem, Inc. (CA) | 2001-02-28 | — | — | EP | disclosed |
| EP-1054664-A1 | METHOD FOR MODULATING MACROPHAGE ACTIVATION | Neurochem, Inc. (CA) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000006133-A2 | COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH GLYCOSAMINOGLYCAN-ASSOCIATED MOLECULAR INTERACTIONS | NEUROCHEM, INC. (CA) | 2000-02-10 | — | — | WO | disclosed |
| WO-1999059571-A1 | USE OF AMYLOID INHIBITORS FOR MODULATING NEURONAL CELL DEATH | NEUROCHEM, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999040909-A1 | METHOD FOR MODULATING MACROPHAGE ACTIVATION | NEUROCHEM, INC. (CA) | 1999-08-19 | — | — | WO | disclosed |
| US-5840294-A | INHIBITING AMYLOID DEPOSITION BY ADMINISTERING A THERAPEUTIC COMPOUND COMPRISING AN ANIONIC GROUP AND A CARRIER MOLECULE | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-11-24 | — | — | US | disclosed |
| EP-0814842-A1 | METHOD FOR TREATING AMYLOIDOSIS | Queen's University at Kingston (CA) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996028187-A1 | METHOD FOR TREATING AMYLOIDOSIS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030003141-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | APP, PYGB, MAPT | MYC 3049/4885TSHR 4800/4885SMN1; SMN2 532/4885 |
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | APP, PYGB, MAPT | MYC 3049/4885TSHR 4800/4885SMN1; SMN2 532/4885 |
| US-20060116347-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CSGALNACT1, CD44 | MYC 3705/4885TSHR 3280/4885SMN1; SMN2 3146/4885 |
| US-20080249184-A1 | Methods for modulating neuronal cell death | GAP43, BAD, NLN | MYC 4339/4885TSHR 3830/4885SMN1; SMN2 137/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | MYC 2814/4885TSHR 2787/4885SMN1; SMN2 2698/4885 |
| US-20040220138-A1 | Methods for modulating neuronal cell death | NLN, GAP43, BAD | MYC 4632/4885TSHR 3412/4885SMN1; SMN2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.